Old drug, new trick: bexarotene may Re-Sensitize resistant breast cancer

This early study tested whether bexarotene, a drug already used for skin lymphoma, could make aggressive triple-negative breast cancer cells that stopped responding to taxane chemotherapy become sensitive again. 12 women with metastatic disease whose cancer had progressed after taxane treatment received bexarotene before their next chemo. The main goal was to measure changes in tumor genes and proteins, not to treat the cancer directly. This was a small, early-phase study focused on understanding the biology, not on proving a cure.